HospiMedica

Download Mobile App
Recent News AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

Antibodies Disappear in 10% of Coronavirus-Recovered Patients and 5% Test Positive Again In New Study

By HospiMedica International staff writers
Posted on 10 Aug 2020
Illustration
Illustration
A study has revealed that antibodies against the novel coronavirus disappeared in 10% of a sample group of COVID-19-recovered patients, 5% were again in quarantine after testing positive for the virus, and 90% reported lung damage.

A team of researchers at the Zhongnan Hospital of Wuhan University (Wuhan, China) has been conducting follow-up visits with 100 coronavirus-recovered patients since April, with the first phase of the one-year program completed in July. Results from the first phase showed that the lungs were still in a damaged state in 90% of the patients, suggesting that the ventilation and gas exchange functions of their lungs have yet to recover to the level of healthy people. Additionally, a walking test revealed that the COVID-19-recovered patients could only walk 400 meters in six minutes as compared to 500 meters by their healthy peers. Moreover, some recovered patients were still dependent on oxygen machines even three months after being discharged from the hospital.

The researchers also found that antibodies against the novel coronavirus had disappeared in 10% of the patients. Out of the sample group of 100 COVID-19-recovered patients, 5% received negative results in COVID-19 nucleic acid tests, but positive results in Immunoglobulin M (IgM) tests, leading them to be quarantined once again. The immune systems of the patients showed a low level of B cells, but a high level of T cells which only recognize viral antigens outside infected cells, indicating that they have not yet fully recovered. The findings are significant as the coronavirus first emerged in Wuhan city.

Related Links:

Zhongnan Hospital of Wuhan University

Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Silver Member
X-Ray QA Device
Accu-Gold+ Touch Pro
Mammography System (Analog)
MAM VENUS

Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more